MedTrace Logo

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

NCT00539500 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2019-07-26

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn how long it takes for certain types of transplanted stem cells to produce new blood cells. The safety of this treatment will also be studied. Finally, researchers want to learn if collecting the cells with the CliniMACS device can decrease the possibility of tumor cells contaminating (appearing in) the stem cells that are reinfused into participants.

Conditions

Interventions

DRUG

Carboplatin

Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.

DRUG

Etoposide

300 mg/m\^2 by vein over 24 hours for 4 days

DRUG

Melphalan

70 mg/m\^2 Intravenous Bolus for 3 Days

PROCEDURE

Stem Cell Infusion

Stem Cell Infusion (approximately 5x10\^8 TNC cells/kg CD133+ selected) on Day 0.

DEVICE

ClinicMACS

Device used to process the blood and separate the CD 133+ cells needed for transplantation

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Laura L. Worth, MD, PhD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2012-09-05
Completion
2012-09-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00539500 on ClinicalTrials.gov